Hybribio Biotech gains patent for antibiotic testing kit

Guangdong Hybribio Biotech (SZSE:300639) announced that it and its subsidiaries have received patent authorization in China for an "Antibiotic Concentration Detection Kit and Its Application." The patented invention focuses on blood drug concentration monitoring technology and offers a reagent kit for detecting concentrations of vancomycin, meropenem, teicoplanin, and voriconazole simultaneously, with accuracy comparable to liquid chromatography-mass spectrometry. The company believes this development will enhance its intellectual property portfolio, boost its core competitiveness, and contribute to the advancement of personalized medication strategies in clinical settings, aligning with its strategic goals of becoming a leading enterprise in molecular diagnostics.